Skip to main content
Context Therapeutics Inc. logo

Context Therapeutics Inc. — Investor Relations & Filings

Ticker · CNTX ISIN · US21077P1084 LEI · 549300U5ISIWCBXD6W77 US Manufacturing
Filings indexed 277 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US CNTX

About Context Therapeutics Inc.

https://www.contexttherapeutics.com/

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to advancing treatments for solid tumors. The company develops next-generation T cell engaging (TCE) bispecific antibody therapies designed to harness the patient's immune system for targeted cancer eradication. Its pipeline features innovative immunotherapeutic solutions for difficult-to-treat solid tumors. Key portfolio highlights include CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody; CT-95, an avidity-enhanced mesothelin (MSLN) x CD3 bispecific antibody; and CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific antibody.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-18 English
ARS - Context Therapeutics Inc. (0001842952) (Filer)
Annual Report
2026-04-28 English
8-K - Context Therapeutics Inc. (0001842952) (Filer)
Regulatory Filings
2026-04-02 English
S-8 - Context Therapeutics Inc. (0001842952) (Filer)
Registration Form
2026-03-23 English
8-K - CONTEXT THERAPEUTICS INC. (0001842952) (Filer)
Regulatory Filings
2026-02-27 English
4 - CONTEXT THERAPEUTICS INC. (0001842952) (Filer)
Director's Dealing
2026-02-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.